Michael Crowther (he/him)
@mikecrowther.bsky.social
Post-Doctoral researcher working with genetically engineered Tumour Infiltrating Lymphocytes (TILs), based in Copenhagen, Denmark
Reposted by Michael Crowther (he/him)
🚨Our Nov issue is live - thelancet.com/issue/S1470-...
📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma
📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma
📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
October 28, 2025 at 9:39 AM
🚨Our Nov issue is live - thelancet.com/issue/S1470-...
📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma
📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
📊Articles: #breastcancer, #NSCLC, #prostatecancer, #melanoma
📰 Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO)
✨️ New review article landed ✨️
Very excited to share the news that our latest review into genetically engineered TILs has just been published in the @thelancetoncol.bsky.social
Many thanks to Özcan Met, Joel, and Inge Marie for their help in writing this!
www.sciencedirect.com/science/arti...
Very excited to share the news that our latest review into genetically engineered TILs has just been published in the @thelancetoncol.bsky.social
Many thanks to Özcan Met, Joel, and Inge Marie for their help in writing this!
www.sciencedirect.com/science/arti...
Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering
Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating lymphocytes (TILs) have greatly im…
www.sciencedirect.com
November 5, 2025 at 11:38 AM
✨️ New review article landed ✨️
Very excited to share the news that our latest review into genetically engineered TILs has just been published in the @thelancetoncol.bsky.social
Many thanks to Özcan Met, Joel, and Inge Marie for their help in writing this!
www.sciencedirect.com/science/arti...
Very excited to share the news that our latest review into genetically engineered TILs has just been published in the @thelancetoncol.bsky.social
Many thanks to Özcan Met, Joel, and Inge Marie for their help in writing this!
www.sciencedirect.com/science/arti...
Happy to share the new article titled 'Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease' published this week in Investigative Opthalmology & Visual Science.
iovs.arvojournals.org/article.aspx...
iovs.arvojournals.org/article.aspx...
Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease | IOVS | ARVO Journals
iovs.arvojournals.org
February 13, 2025 at 10:54 AM
Happy to share the new article titled 'Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease' published this week in Investigative Opthalmology & Visual Science.
iovs.arvojournals.org/article.aspx...
iovs.arvojournals.org/article.aspx...
Looking forward to seeing the peer reviewed paper of this preprint, as highlighted by @natrevimmunol.bsky.social
Method of engineering TILs using pMHC pseuodtyped retroviruses!
www.biorxiv.org/content/10.1...
Method of engineering TILs using pMHC pseuodtyped retroviruses!
www.biorxiv.org/content/10.1...
In vivo enhancement of tumour-specific T cells via peptide–MHC-pseudotyped retroviral gene delivery
Nature Reviews Immunology - A preprint by Xu et al. shows that MHC-pseudotyped retroviruses can reprogramme, activate and expand tumour-specific T cell populations in vivo.
rdcu.be
January 9, 2025 at 3:02 PM
Looking forward to seeing the peer reviewed paper of this preprint, as highlighted by @natrevimmunol.bsky.social
Method of engineering TILs using pMHC pseuodtyped retroviruses!
www.biorxiv.org/content/10.1...
Method of engineering TILs using pMHC pseuodtyped retroviruses!
www.biorxiv.org/content/10.1...
A follow up study to the Nature Immunology paper we published on the MR1-restricted T-cells (MC.7.G5) that respond to cancer! This time, cancer specific recognition of cancer cell lines through the use of a semi-invariant TCR containing a TRAJ42 segment and a CAXYGGSQGNLIF TCRα motif.
JCI -
MHC-related protein 1–restricted recognition of cancer via a semi-invariant TCR-α chain
www.jci.org
January 3, 2025 at 10:06 AM
A follow up study to the Nature Immunology paper we published on the MR1-restricted T-cells (MC.7.G5) that respond to cancer! This time, cancer specific recognition of cancer cell lines through the use of a semi-invariant TCR containing a TRAJ42 segment and a CAXYGGSQGNLIF TCRα motif.
Reposted by Michael Crowther (he/him)
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
December 12, 2024 at 7:02 PM
Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn
Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn